SmarterAnalyst
Emergency Use List Granted for Johnson & Johnson COVID-19 Single Dose Vaccine by WHO
The Johnson & Johnson COVID-19 single dose vaccine, developed by Johnson & Johnson’s Janssen Pharmaceutical Companies (Janssen), has received an emergency use list (EUL) by the World Health Organization (WHO). The world’s largest healthcare company developed the vaccine to prevent COVID-19 in individuals 18 years of age or older. Data released from the Phase 3 ENSEMBLE study reflected that the Johnson & Johnson single dose COVID-19 vaccine (JNJ) has a favorable tolerability profile. In addition, the study confirmed that the reduction in symptomatic COVID-19 disease in subjects who received the vaccine compared to subjects who received the placebo was 67%. In addition, the data confirmed the vaccine’s 85% effectiveness in preventing serious illnesses in all regions studied and demonstrated that the vaccine protects against hospitalization and death due to COVID-19 in countries with different variants, starting 28 days after vaccination . Last December, Johnson & Johnson and Gavi, the Vaccine Alliance, agreed in principle to support the COVAX Facility. Both are likely to enter into an advance purchase agreement (PAC) that will provide the company’s 500 million doses of the vaccine for COVAX by 2022. (See Johnson & Johnson inventory analysis at TipRanks) Johnson & Johnson VC Executive Committee Paul Stoffels said: “The WHO listing of our single-dose COVID-19 vaccine advances our promise to help contain this pandemic and our unwavering commitment to equitable access. ”“ Achieving this important prerequisite for distributing our vaccine through the COVAX Facility, which is co-led by Gavi, is a big step towards making our vaccine accessible to everyone, ”added Stoffels. In recent months, the company has also received the Emergency Use Authorization (USA) for the vaccine in the USA by the Food and Drug Administration (FDA) and the Provisional Order authorization in Canada, along with the Conditional Marketing Authorization (CMA) at European Union. On January 27, JP Morgan analyst Chris Schott raised the stock price target from $ 157 to $ 175 (9.7% upside potential) and reiterated the Hold rating “after the fourth quarter results quarter of the company. ” The consensus rating among analysts is a strong buy based on 10 purchases versus 1 wait. The average target price of the analyst is $ 189.90 and implies a potential increase of 19% to current levels. The shares gained 25.5% last year. In addition, Johnson & Johnson obtained a “Perfect 10” in TipRanks’ Smart Score rating system, indicating that the stock has strong potential to exceed market expectations. Related news: Altimmune extends partnership with Lonza to support the production of cardinal health paints AdCOVID $ 1 billion offer to sell Cordis Business Sanofi, Translate Bio Kick Off Human COVID-19 Vaccine Trial; Shares Earn 5% Latest Articles from Smarter Analyst: Century Casinos Earns 4% in 4Q Profit Win Four Corners Buys Gauge Collision Property for $ 1.9 Million Charles Schwab’s Brokerage Accounts and Client Assets Rise Equity Lifestyle increases the quarterly dividend by 5.8%; The street sees a 10% advantage